BIOA News

Latest breaking news and updates for BIOA stock.

Track all markets on TradingView

BioAge Labs Announces First Participant Dosed in Phase 1 Clinical Trial of BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile

What is the anticipated competitive landscape if BGE-102 advances to Phase 2/3 for CNS diseases? How could the trial’s outcomes impact BIOA’s cash burn rate and need for future financing? Will the Phase 1 enrollment numbers and dosing strategy provide sufficient data to de‑risk later‑stage development?
Clinical trials
8 days ago
Read more globenewswire

BioAge Labs Reports Second Quarter 2025 Financial Results and Provides Business Updates

Oral NLRP3 inhibitor BGE-102 on track for Phase 1 initiation in 2H 2025 with initial data by year-end

Does the company’s updated financial guidance suggest a need for equity or debt financing, and how could that affect dilution concerns? What are the potential upside or downside scenarios for BIOA’s valuation based on the timing and success of the BGE‑102 data read‑out? How might the updated Phase 1 timeline affect the competitive landscape with other NLRP3 or inflammasome therapeutics in development?
Earnings
16 days ago
Read more globenewswire